APTADIR RAISES A €40M ($45M) SEED FINANCING TO ADVANCE FIRST-IN-CLASS DEMETHYLATING MEDICINES
Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation from the company’s original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National…